Akèy › Kansè pwostat rezistan a kastasyon
Etid klinik pou Kansè pwostat rezistan a kastasyon ap rekrite nan Etazini
18 etid pou Kansè pwostat rezistan a kastasyon ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Los Angeles, CA8 etid
- New York City, NY7 etid
- Seattle, WA6 etid
- Houston, TX6 etid
- Boston, MA5 etid
- Queens, NY4 etid
- Philadelphia, PA4 etid
- Pittsburgh, PA4 etid
- Mountain View, CA3 etid
- Grand Rapids, MI3 etid
- Myrtle Beach, SC3 etid
- Nashville, TN3 etid
- St. Louis, MO3 etid
- Metairie, LA3 etid
- Minneapolis, MN3 etid
- Cincinnati, OH3 etid
- San Francisco, CA3 etid
- Baltimore, MD3 etid
- Dallas, TX3 etid
- Arlington, VA3 etid
- San Diego, CA3 etid
Pa eta
- Connecticut3 etid
- Florid5 etid
- Illinois3 etid
- Kalifòni11 etid
- Lwizyàn3 etid
- Maryland3 etid
- Massachusetts5 etid
- Michigan7 etid
- Minnesota4 etid
- Missouri3 etid
- Nebraska3 etid
- New Jersey4 etid
- New York8 etid
- North Carolina4 etid
- Ohio4 etid
- Oregon3 etid
- Pennsylvania5 etid
- South Carolina4 etid
- Tennessee5 etid
- Texas7 etid
- Virginia4 etid
- Washington6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT07164443A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07225946A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 24, 2026 · NCT07719361Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06353386A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06863272Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 10, 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
Laj 18 a 100 · Gason · Mizajou Aug 13, 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Aug 10, 2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Ap rekriteEtid obsèvasyon
Laj 18 a 115 · Gason · Mizajou Jul 16, 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteEtid obsèvasyon
Laj 18 a 115 · Gason · Mizajou Jul 16, 2026 · NCT07677254A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Gason · Mizajou May 29, 2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Ap rekriteFaz 1/2
Laj 18 ak plis · Gason · Mizajou May 6, 2026 · NCT04868604Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Apr 13, 2026 · NCT04337580Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Gason · Mizajou Apr 13, 2026 · NCT06190899Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Nov 21, 2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Ap rekriteFaz 4
Laj 18 ak plis · Gason · Mizajou Nov 27, 2024 · NCT06706921Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.